Financial Performance - The company's operating revenue for Q1 2022 was ¥50,357,114.91, a decrease of 28.96% compared to ¥70,884,919.88 in the same period last year[3] - The net profit attributable to shareholders was -¥23,275,808.58, representing a decline of 75.43% from -¥13,267,948.59 year-on-year[3] - The net loss for the current period was CNY 25,909,848.63, compared to a net loss of CNY 14,969,513.54 in the previous period[16] - The total comprehensive income for the period was -25,909,848.63 CNY, compared to -14,969,513.54 CNY in the previous year[20] - Basic and diluted earnings per share were both -0.0226 CNY, worsening from -0.0129 CNY in the same quarter last year[20] Cash Flow and Liquidity - The net cash flow from operating activities improved by 55.79%, amounting to -¥7,374,282.57 compared to -¥16,678,791.31 in the previous year[3] - Cash and cash equivalents at the end of the period were 28,308,162.95 CNY, down from 35,891,192.89 CNY at the end of the previous year[21] - The company did not report any cash inflow from investment activities, resulting in a net cash flow from investing activities of -1,779,000.00 CNY[21] - The net cash flow from financing activities was -387,375.01 CNY, compared to -188,250.01 CNY in the previous year[21] Assets and Liabilities - Total assets decreased by 7.17% to ¥741,995,891.33 from ¥799,312,074.12 at the end of the previous year[3] - Total liabilities decreased to CNY 121,129,369.35 from CNY 152,535,703.51, a decrease of approximately 20.6%[13] - The company's total equity decreased to CNY 620,866,521.98 from CNY 646,776,370.61, a decline of about 4.0%[13] Research and Development - The company's R&D expenses were ¥13,931,832.09, down 32.63% from ¥20,679,688.39 in the same period last year, indicating a slowdown in R&D progress[6] - Research and development expenses were CNY 13,931,832.09, down from CNY 20,679,688.39, a decrease of approximately 32.5%[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 116,524[8] - The top shareholder, Wang Hongming, holds 14.00% of the shares, totaling 144,138,394 shares[8] Credit and Impairment - The company reported a significant increase in credit impairment losses, with a rise of 2319.16% to -¥5,636,224.03 due to adjustments in expected credit loss rates[6] Product Development and Market Strategy - The company did not report any new product developments or market expansion strategies during this quarter[10] - There were no new product launches or significant technological advancements reported during the quarter[20] Audit Status - The report was not audited, indicating that the figures may be subject to change upon further review[22]

Financial Performance - The company's operating revenue for 2021 was ¥350,961,775.85, a decrease of 30.56% compared to ¥505,399,427.19 in 2020[19] - The net profit attributable to shareholders was -¥34,789,910.35, representing a decline of 227.46% from a profit of ¥27,295,103.63 in the previous year[19] - The net cash flow from operating activities was ¥155,654.35, down 99.84% from ¥100,233,420.61 in 2020[19] - The total assets at the end of 2021 were ¥799,312,074.12, a decrease of 2.96% from ¥823,707,532.72 at the end of 2020[19] - The net assets attributable to shareholders decreased by 5.43% to ¥606,033,621.98 from ¥640,823,532.33 in 2020[19] - The basic earnings per share for 2021 was -¥0.0338, a decline of 227.55% compared to ¥0.0265 in 2020[19] - The weighted average return on equity was -5.71%, down from 4.35% in the previous year, indicating a significant decline in profitability[19] - The company reported a significant drop in both revenue and profit, indicating challenges in its operational performance[19] Cash Flow and Investments - Operating cash inflow decreased by 23.65% to ¥358,955,016.29, while cash outflow decreased by 3.00% to ¥358,799,361.94[60] - Net cash flow from operating activities plummeted by 99.84% to ¥155,654.35 in 2021[61] - Investment cash inflow dropped by 67.49% to ¥318,002.86, with net cash flow from investment activities at -¥9,181,393.52[61] - Financing cash inflow decreased by 6.98% to ¥16,000,000.00, while cash outflow fell by 77.99% to ¥23,703,331.44, resulting in a net cash flow of -¥7,703,331.44[61] Revenue Sources and Product Performance - The pharmaceutical segment generated revenue of CNY 291,331,416.65, down 5.66% from the previous year, accounting for 83.01% of total revenue[41] - Sales of EPO reached CNY 133,616,871.05, accounting for 38.07% of total revenue, with a year-on-year increase of 10.66%[42] - The company’s main products include recombinant human interleukin-2 and granulocyte colony-stimulating factor, which are critical for cancer treatment and recovery from chemotherapy[33] - The gross margin for the pharmaceutical segment was 77.53%, with a slight decrease of 3.02% compared to the previous year[45] Research and Development - The company holds 5 invention patents and 3 new drug certificates, indicating a strong focus on R&D[39] - Research and development expenses increased by 27.35% year-on-year, amounting to 51,836,224.41 yuan[56] - R&D investment rose by 27.35% to ¥51,836,224.41 in 2021, representing 14.77% of operating revenue, up from 8.05% in 2020[58] - R&D personnel increased by 75% from 16 in 2020 to 28 in 2021, accounting for 11.02% of total employees[58] - The company is developing a new long-acting recombinant human erythropoietin, which aims to enhance market competitiveness[57] - The company is also working on a new anti-cataract drug, recombinant hirudin III eye drops, which is expected to create new revenue growth points upon market entry[57] Governance and Compliance - The company has established a dedicated investor relations management system to ensure accurate and timely communication with all investors[83] - The board of directors consists of six members, including three independent directors, and has established four specialized committees to enhance governance[82] - The company has completed the rectification of issues identified in the special governance action as required by regulatory authorities, ensuring compliance with governance standards[81] - The independent directors actively participate in training to stay informed about relevant laws and regulations, ensuring they can effectively protect minority shareholders' rights[82] - The company is committed to maintaining the rights of all shareholders, especially minority shareholders, through improved governance mechanisms[101] Market and Industry Context - The pharmaceutical industry in China is experiencing a compound annual growth rate (CAGR) of 13.71% from 2010 to 2020, highlighting the increasing importance of healthcare spending[30] - The company is positioned to benefit from the ongoing healthcare reforms in China, which aim to improve drug accessibility and promote high-quality medical services[31] - The company is focused on the development of innovative drugs, particularly in the oncology sector, aligning with national policies that encourage drug innovation and procurement reforms[32] Risks and Challenges - The company has acknowledged risks related to its future development and ongoing operations, which may impact investor decisions[5] - The company faces risks from the ongoing COVID-19 pandemic, which may impact production operations and increase costs related to raw materials and logistics[76] - The company is facing significant uncertainties regarding its ability to continue as a going concern, which may impact future financial performance[188] - The company has significant inventory risks related to nursery stock, which has not met expected turnover rates, impacting financial conditions[78] - The company is involved in ongoing litigation related to securities false statements, with uncertain impacts on future profits[78] Shareholder Structure - The total number of ordinary shareholders at the end of the reporting period was 118,246, an increase from 116,524 at the end of the previous month, representing a growth of approximately 1.48%[160] - The largest shareholder, Wang Hongming, holds 14.00% of the shares, totaling 144,138,394 shares, with 144,130,000 shares pledged[160] - The second-largest shareholder, Yu Qinfeng, owns 10.13% of the shares, amounting to 104,318,725 shares, with 99,860,000 shares pledged[160] - The company has no controlling shareholder, with the top three shareholders holding similar proportions[163] Employee and Management Structure - The total number of employees at the end of the reporting period was 254, with 110 in production, 22 in sales, 71 in technical roles, and 16 in finance[105] - The company has a training plan in place to enhance the overall quality and business skills of its personnel, including both internal and external training programs[108] - The financial team is led by Xu Haizhen, who has extensive experience in accounting and financial management, ensuring robust financial oversight[92] Legal and Regulatory Issues - The company faced penalties from the China Securities Regulatory Commission and Shenzhen Stock Exchange for information disclosure violations in 2020 and 2021[93] - The company has faced public reprimands from the stock exchange for information disclosure violations involving several senior management personnel[137] - The company is actively responding to ongoing litigation and will continue to monitor the situation closely[129]

Financial Performance - Revenue for Q3 2021 was ¥86,458,898.73, a decrease of 26.63% compared to the same period last year[3] - Net profit attributable to shareholders was ¥4,888,094.18, down 68.37% year-on-year[3] - The company reported a net loss of CNY 24.53 million for Q3 2021, compared to a profit of CNY 25.99 million in the same quarter last year[21] - The net profit for Q3 2021 was -25,781,383.17 CNY, a significant decline compared to the net profit of 21,688,750.59 CNY in the same period last year[22] - The net profit attributable to the parent company was -22,781,213.47 CNY, compared to 21,751,604.18 CNY in Q3 2020[22] - Basic earnings per share were ¥0.0047, a decrease of 68.67% compared to the same period last year[3] - The basic and diluted earnings per share were both -0.0221 CNY, down from 0.0211 CNY in the previous year[22] Cash Flow and Liquidity - The net cash flow from operating activities was -¥12,202,601.96, representing a decline of 114.84% compared to the previous year[9] - Cash received from operating activities decreased by 30.76% to ¥249,811,207.55 compared to the same period last year[9] - Cash flow from operating activities showed a net outflow of -12,202,601.96 CNY, a decrease from a net inflow of 82,254,593.09 CNY in Q3 2020[25] - Total cash inflow from operating activities was 265,224,529.22 CNY, down from 364,503,620.76 CNY in the same period last year[25] - Cash outflow from operating activities totaled 277,427,131.18 CNY, slightly lower than 282,249,027.67 CNY in Q3 2020[25] - The ending cash and cash equivalents balance was 38,157,174.12 CNY, a slight decrease from 38,417,040.81 CNY at the end of Q3 2020[26] - The company's cash and cash equivalents decreased from ¥54,591,460.06 at the end of 2020 to ¥38,157,174.12 by September 30, 2021, a decline of approximately 30%[17] Assets and Liabilities - Total assets at the end of the reporting period were ¥805,916,743.82, a decrease of 2.16% from the end of the previous year[3] - Total assets decreased to CNY 805.92 million, down from CNY 823.71 million year-over-year[19] - Current liabilities decreased to CNY 103.83 million, a reduction of 24.61% from CNY 137.66 million in the previous year[19] - Non-current liabilities increased to CNY 42.82 million, compared to CNY 1.00 million in the same period last year[19] - The company's total equity decreased to CNY 659.27 million, down from CNY 685.05 million year-over-year[19] - Total equity attributable to shareholders was ¥618,042,318.86, down 3.55% from the previous year[4] Research and Development - Research and development expenses increased by 110.55% to ¥59,102,128.14 due to new project expenditures[9] - Research and development expenses increased significantly to CNY 59.10 million, up 110.81% from CNY 28.07 million in the previous year[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 118,448[11] - The largest shareholder, Wang Hongming, holds 14.00% of shares, totaling 144,138,394 shares[12] - The company has a total of 10 major shareholders, with the top three holding a combined 32.74% of shares[12] Legal Matters - The company has ongoing litigation with a total claim amounting to ¥266,767,130.02 related to investment losses[13] - The company is committed to timely information disclosure regarding ongoing litigation and other significant matters[14] Contracts and Projects - The company has completed construction work worth ¥28,337,500 under a contract with Shandong Zhongchuan, which was terminated in 2021[15] - The company has a contract with Shandong Zhongchuan for a total project amount of approximately ¥1 billion, with a minimum of ¥500 million allocated for landscaping[14] Operational Performance - The company reported a significant decrease in operating income due to the disposal of equity in Guangxi Intercontinental[9] - Total operating revenue for Q3 2021 was CNY 236.21 million, a decrease of 33.33% compared to CNY 354.41 million in the same period last year[21] - Total operating costs for Q3 2021 were CNY 262.76 million, down 18.99% from CNY 324.80 million year-over-year[21]

Financial Performance - The company's operating revenue for the reporting period was ¥149,748,660.35, a decrease of 36.70% compared to ¥236,569,960.74 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was -¥27,669,307.65, representing a decline of 539.43% from ¥6,296,576.38 in the previous year[20]. - The net cash flow from operating activities was -¥12,832,855.88, down 119.86% from ¥64,607,780.69 in the same period last year[20]. - The basic earnings per share were -¥0.0269, a decrease of 540.98% compared to ¥0.0061 in the previous year[20]. - The company reported a net loss of CNY 490,708,726.40 in retained earnings, worsening from a loss of CNY 463,039,418.75 at the end of 2020[107]. - The net loss for the first half of 2021 was CNY 31.57 million, compared to a net profit of CNY 4.52 million in the same period of 2020[115]. - The total comprehensive income for the period was 11,325.59 million yuan, showcasing the company's robust performance despite market challenges[134]. Assets and Liabilities - Total assets at the end of the reporting period were ¥817,762,509.17, a decrease of 0.72% from ¥823,707,532.72 at the end of the previous year[20]. - The net assets attributable to shareholders of the listed company were ¥613,154,224.68, down 4.32% from ¥640,823,532.33 at the end of the previous year[20]. - Total liabilities increased to CNY 164,285,125.32 from CNY 138,659,527.09, marking an increase of approximately 18.4%[106]. - The total liabilities of the company were not detailed in the provided documents, indicating a focus on equity rather than debt management[130]. Revenue Segmentation - The pharmaceutical segment generated ¥127,784,414.56, accounting for 85.33% of total revenue, with a year-on-year increase of 32.49%[35]. - The landscape engineering segment's revenue was ¥7,655,267.02, showing a growth of 4.01% compared to the previous year[35]. - Total operating revenue for the first half of 2021 was CNY 149.75 million, a decrease of 36.67% compared to CNY 236.57 million in the same period of 2020[112]. Research and Development - Research and development expenses increased by 201.15% to ¥41,376,753.42, reflecting the addition of new R&D projects[33]. - The company holds 5 invention patents and 3 new drug certificates, indicating a strong position in biopharmaceutical R&D[31]. - The company is focusing on research and development of new technologies to drive future growth and innovation in its product offerings[134]. Cash Flow and Financing - Cash and cash equivalents decreased to ¥39,469,926.67, representing 4.83% of total assets, down from 6.63% last year, a decrease of 1.80%[39]. - The company incurred a net cash outflow from investing activities of CNY -1,957,318.77, compared to a net outflow of CNY -1,680,805.63 in the previous year[124]. - The company received CNY 16,000,000.00 from borrowings, which was consistent with the previous year, indicating stable financing activities[124]. Shareholder Information - The company reported a total of 1,029,556,222 shares outstanding, with 100% being unrestricted shares[89]. - The total number of ordinary shareholders at the end of the reporting period was 127,376[91]. - The largest shareholder, Wang Hongming, holds 14.00% of the shares, amounting to 144,138,394 shares, with a pledge on 144,130,000 shares[91]. Corporate Governance and Compliance - The company has not engaged in any significant related party transactions during the reporting period[72]. - The company and its subsidiaries are not classified as key pollutant discharge units and have not faced any environmental penalties[59]. - There were no major contracts or leasing matters reported during the period[78]. Market and Industry Context - The pharmaceutical industry is characterized by strong demand and is less affected by macroeconomic fluctuations, with increasing importance in the national economy[28]. - The company faces risks related to industry policies, R&D, accounts receivable management, and inventory management, which may impact operations and financial performance[49][50]. Accounting and Financial Reporting - The financial statements are prepared based on the going concern assumption and comply with the relevant accounting standards[141]. - The company recognizes expected credit losses for financial assets, with provisions based on the expected credit loss over the entire life of the asset[169]. - The company uses Renminbi as its functional currency for accounting purposes[147].

Financial Performance - The company's revenue for Q1 2021 was ¥70,884,919.88, a decrease of 54.85% compared to ¥157,012,600.06 in the same period last year[8] - The net profit attributable to shareholders was a loss of ¥13,267,948.59, representing a decline of 228.70% from a profit of ¥10,309,269.64 in the previous year[8] - Basic and diluted earnings per share were both -¥0.0129, a decrease of 229.00% compared to ¥0.0100 in the previous year[8] - The net profit for Q1 2021 was CNY -14,969,513.54, compared to a net profit of CNY 8,292,715.46 in the same period last year, indicating a significant decline[39] - The total comprehensive income for Q1 2021 was CNY -14,969,513.54, compared to CNY 8,292,715.46 in the previous year[39] Cash Flow - The net cash flow from operating activities was negative at ¥16,678,791.31, down 149.03% from ¥34,016,509.11 in the same period last year[8] - Cash flow from operating activities was CNY 76,315,858.06, down from CNY 123,924,137.47 in the previous year, reflecting a decrease of 38.3%[45] - The net cash flow from operating activities was -16,678,791.31 CNY, a decrease compared to 34,016,509.11 CNY in the previous period[46] - Total cash inflow from operating activities was 76,351,722.83 CNY, while cash outflow was 93,030,514.14 CNY, resulting in a net cash outflow of 16,678,791.31 CNY[46] Assets and Liabilities - Total assets at the end of the reporting period were ¥823,330,609.39, a slight decrease of 0.05% from ¥823,707,532.72 at the end of the previous year[8] - The net assets attributable to shareholders decreased by 2.07% to ¥627,555,583.74 from ¥640,823,532.33 at the end of the previous year[8] - Total liabilities increased to CNY 140,260,056.54 in Q1 2021, compared to CNY 137,613,291.18 in the previous quarter[34] - Total liabilities reached CNY 183,000,145.70, indicating an increase of CNY 44,340,618.61 from the previous period[54] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 132,319[11] - The top shareholder, Wang Hongming, holds 14.00% of the shares, totaling 144,138,394 shares[11] Operating Performance - Operating revenue fell by 54.85% year-on-year, from CNY 157,012,600.06 to CNY 70,884,919.88, primarily due to a decrease in material forest sales[15] - Operating costs decreased by 77.33% from CNY 81,342,214.91 to CNY 18,443,116.03, also attributed to reduced material forest sales[15] - The company reported a 100.00% decrease in other operating expenses, dropping from CNY 992,545.00 to CNY 0.00[15] Research and Development - R&D expenses surged by 710.00% from CNY 2,553,049.60 to CNY 20,679,688.39, driven by increased promotional consulting fees[15] - Research and development expenses increased significantly to CNY 20,679,688.39, compared to CNY 2,553,049.60 in the previous year, reflecting a growth of 707.5%[37] Management and Governance - The company’s chairman is Guo Yu, who presented the first quarter report on April 28, 2021[60] - The first quarter report has not been audited, indicating potential for adjustments in future reports[59] Other Information - The company received government subsidies amounting to ¥4,118.28 during the reporting period[9] - There were no new product developments or market expansions mentioned in the report[39] - The company did not report any significant mergers or acquisitions during this period[39] - The company has not disclosed any new product developments or market expansion strategies in this report[60]

Financial Performance - The company's operating revenue for 2020 was CNY 505,399,427.19, representing a 20.94% increase compared to CNY 417,878,239.86 in 2019[18]. - The net profit attributable to shareholders for 2020 was CNY 27,295,103.63, a significant increase of 90.46% from CNY 14,330,773.52 in 2019[18]. - The net cash flow from operating activities reached CNY 100,233,420.61, up 70.95% from CNY 58,632,435.61 in the previous year[18]. - The basic earnings per share for 2020 was CNY 0.0265, reflecting a 90.65% increase from CNY 0.0139 in 2019[18]. - Total revenue for 2020 reached ¥505.40 million, a year-on-year increase of 20.94% compared to ¥417.88 million in 2019[39]. - The company reported a total comprehensive income of CNY 27.66 million for 2020, compared to CNY 17.50 million in 2019, marking a growth of 58.2%[189]. - The company’s total operating costs rose to CNY 474.97 million in 2020 from CNY 387.01 million in 2019, an increase of 22.6%[191]. Assets and Liabilities - Total assets at the end of 2020 were CNY 823,707,532.72, a decrease of 10.06% from CNY 915,826,035.12 at the end of 2019[18]. - The total liabilities also decreased from CNY 255.51 million in 2019 to CNY 138.66 million in 2020, a reduction of 45.68%[180]. - The total current assets amounted to CNY 668,928,560.78 as of December 31, 2020, down from CNY 755,852,139.94 in the previous year, indicating a decrease of about 11.5%[178]. - The total inventory accounted for 55.35% of the total assets as of December 31, 2020, highlighting the significant role of inventory in the company's asset structure[171]. Revenue Segmentation - The core products of the subsidiary Beijing Four环生物制药 experienced a slight decline in revenue, totaling CNY 308,814,960.93, down 8.51% year-on-year due to the impact of the pandemic and medical reform policies[35]. - The timber business of the wholly-owned subsidiary Guangxi Intercontinental Forestry Investment achieved operating revenue of CNY 143,858,377.52, a significant increase of 374.20% year-on-year[35]. - Domestic sales accounted for 98.95% of total revenue at ¥500.07 million, up from 97.64% in 2019[40]. - Pharmaceutical segment revenue decreased by 19.68% to ¥308.81 million, accounting for 61.10% of total revenue[39]. - The timber segment saw a significant increase in revenue by 21.20% to ¥143.86 million, representing 28.46% of total revenue[39]. Research and Development - The company has five invention patents and three new drug certificates, indicating a strong focus on research and development in the biopharmaceutical sector[32]. - The company reported a significant increase in the number of R&D personnel, rising by 166.67% from 6 to 16[54]. - Research and development expenses amounted to ¥40,704,876.05, representing 8.05% of total revenue, a decrease from 10.29% in 2019[54]. Governance and Compliance - The company is actively enhancing its internal control system and compliance management following administrative penalties from the China Securities Regulatory Commission[36]. - The company emphasizes the protection of minority shareholders' rights and has established a comprehensive corporate governance structure[106]. - The company faced penalties for information disclosure violations, including warnings and fines for several directors and senior management[88]. - The audit opinion was a standard unqualified opinion, confirming the fair presentation of the financial statements[165]. Shareholder Information - The total number of ordinary shareholders increased from 132,319 to 142,671, indicating a growth of approximately 7.5%[117]. - The largest shareholder, Wang Hongming, holds 14.00% of the shares, amounting to 144,138,394 shares, which are currently pledged[117]. - The company has no controlling shareholders, with the top five shareholders holding similar stakes, promoting a balanced ownership structure[120]. Operational Strategies - The company plans to continue focusing on its core products, including Delu Sheng and Xin Li Sheng, while actively expanding into new markets to increase market share[68]. - The company aims to enhance its production and sales management to reduce pharmaceutical sales expenses and improve operational efficiency[72]. - The company plans to expand its landscaping business to create new profit growth points and improve overall competitiveness[69]. Cash Flow and Financial Management - The total amount of cash inflow from operating activities was ¥470,125,282.10, up 13.22% from ¥415,232,539.07 in 2019[55]. - Cash inflow from financing activities totaled ¥17,200,000.00 in 2020, down from ¥106,000,000.00 in 2019, a decrease of about 83.8%[197]. - The company reported a cash outflow of ¥3,219,138.31 related to other operating activities in 2020, down from ¥4,554,828.80 in 2019, showing a decrease of approximately 29.2%[198]. Employee and Management Structure - The total number of employees in the company is 288, with 238 in major subsidiaries and 7 in the parent company[139]. - The company has a professional composition of 128 production personnel, 22 sales personnel, 79 technical personnel, 12 financial personnel, and 47 administrative personnel[139]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounts to 2.23 million yuan[139]. Audit and Internal Controls - The internal control audit report indicated that the company maintained effective financial reporting internal controls as of December 31, 2020[160]. - There were no significant internal control deficiencies reported during the period[157]. - The company has established an independent financial department and accounting system, ensuring financial decisions are made independently[149].

Financial Performance - Operating revenue for the reporting period was CNY 117,844,923.53, an increase of 5.40% year-on-year, and CNY 354,414,884.27 for the year-to-date, up 24.01% compared to the same period last year[7]. - Net profit attributable to shareholders was CNY 15,455,027.80, down 18.02% year-on-year, while year-to-date net profit reached CNY 21,751,604.18, an increase of 129.49%[7]. - Basic earnings per share for the reporting period were CNY 0.0150, down 18.03%, while year-to-date earnings per share were CNY 0.0211, up 129.35%[7]. - Total operating revenue for the current period reached ¥354,414,884.27, an increase of 24.0% compared to ¥285,787,479.49 in the previous period[46]. - Net profit for the current period was ¥21,688,750.59, a significant increase of 81.7% compared to ¥11,950,960.01 in the same period last year[48]. - Total comprehensive income for the period was ¥17,165,591.27, down from ¥21,922,126.69, reflecting a decrease of about 21.6%[40]. Cash Flow - The net cash flow from operating activities was CNY 17,646,812.40, up 27.62% for the reporting period, and CNY 82,254,593.09 year-to-date, reflecting a significant increase of 671.66%[7]. - The net cash flow from operating activities increased significantly to ¥82,254,593.09 from ¥10,659,499.88, representing a growth of approximately 671.5%[55]. - Cash inflow from operating activities totaled ¥364,503,620.76, up from ¥274,914,877.62, indicating a year-over-year increase of about 32.5%[54]. - The net cash flow from investment activities was negative at -¥7,692,834.78, an improvement from -¥15,769,963.42, showing a reduction in cash outflow by about 51.2%[55]. - The net cash flow from financing activities was -¥89,344,715.07, worsening from -¥1,099,447.57, indicating a significant increase in cash outflow[55]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 813,019,385.78, a decrease of 11.23% compared to the end of the previous year[7]. - Current liabilities decreased significantly from CNY 253,774,281.05 to CNY 132,290,115.66, a reduction of 47.9%[31]. - The company's total liabilities decreased from CNY 255,511,765.13 to CNY 133,939,084.24, a decrease of 47.5%[31]. - Owner's equity increased to CNY 679,080,301.54 from CNY 660,314,269.99, an increase of 2.5%[32]. - Total assets decreased to CNY 813,019,385.78 from CNY 915,826,035.12, a decline of 11.2%[32]. Shareholder Information - The total number of shareholders at the end of the reporting period was 149,904, with the top ten shareholders holding a combined 38.47% of the shares[11]. - The largest shareholder, Wang Hongming, held 14.00% of the shares, amounting to 144,138,394 shares[11]. Operating Costs and Expenses - Operating costs rose by 70.70% to ¥127,585,073.57, attributed to an increase in the proportion of timber sales compared to the previous year[15]. - Total operating costs increased to ¥99,643,407.11 from ¥90,368,380.89, representing an increase of approximately 14.1% year-over-year[38]. - The company’s financial expenses decreased by 75.22% to ¥640,386.11, as a result of reduced loans and interest expenses[15]. Other Financial Metrics - The weighted average return on net assets was 2.49% for the reporting period, a decrease of 0.61%, while it was 3.48% year-to-date, an increase of 1.91%[7]. - The company reported non-operating income and expenses totaling CNY -613,851.36 for the year-to-date, with government subsidies amounting to CNY 3,605,803.61[8]. - The company recorded a 100% decrease in advance receipts, now at ¥0.00, due to reclassification under new revenue standards[15]. - The company reported a net loss of CNY 468,582,918.20, slightly improved from a loss of CNY 490,334,522.38 in the previous period[32].

Financial Performance - The company's operating revenue for the first half of 2020 was CNY 236,569,960.74, representing a 35.97% increase compared to CNY 173,982,059.53 in the same period last year[18]. - The net profit attributable to shareholders of the listed company reached CNY 6,296,576.38, a significant turnaround from a loss of CNY 9,373,965.09 in the previous year, marking a 167.17% increase[18]. - The net profit after deducting non-recurring gains and losses was CNY 9,179,267.14, compared to a loss of CNY 9,819,834.59 in the same period last year, reflecting a 193.48% improvement[18]. - The net cash flow from operating activities was CNY 64,607,780.69, a remarkable increase of 2,139.27% from a negative cash flow of CNY 3,168,184.61 in the previous year[18]. - The company reported a significant reduction in financial expenses by 78.04% due to decreased loans and interest costs[37]. - The company reported a net loss of CNY 484,037,946.00 for the first half of 2020, slightly improved from a loss of CNY 490,334,522.38 in the same period of 2019[112]. - The total profit for the first half of 2020 was CNY 6.38 million, compared to a total loss of CNY 10.63 million in the same period of the previous year[120]. Revenue Breakdown - Revenue from pharmaceutical products decreased by 10% to CNY 124.81 million, accounting for 52.76% of total revenue[39]. - Revenue from timber sales surged by 39.30% to CNY 105.47 million, making up 44.58% of total revenue[39]. - The company's total revenue for the pharmaceutical segment was approximately ¥124.81 million, representing a year-over-year decrease of 10.21%[41]. - The domestic sales revenue reached approximately ¥233.37 million, with a year-over-year growth of 36.69%[41]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 810,490,140.20, down 11.50% from CNY 915,826,035.12 at the end of the previous year[18]. - The company's total liabilities decreased to CNY 145,652,710.89 as of June 30, 2020, down from CNY 255,511,765.13 at the end of 2019, a reduction of approximately 43%[112]. - The company's cash and cash equivalents at the end of the reporting period amounted to approximately ¥27.59 million, increasing its proportion of total assets by 1.57%[43]. - Accounts receivable stood at approximately ¥118.44 million, accounting for 14.61% of total assets, with a slight increase in proportion of 1.76%[43]. - Inventory decreased to approximately ¥482.91 million, representing 59.58% of total assets, down by 4.30% from the previous year[43]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 128,412[89]. - The largest shareholder, Wang Hongming, holds 14.00% of the shares, amounting to 144,138,394 shares, which are pledged[89][90]. - The second-largest shareholder, Kunshan Chuangye Investment Co., Ltd., holds 7.63% of the shares, totaling 78,586,654 shares[90]. - The company has a total of 1,029,556,222 shares outstanding, with no changes reported during the period[86]. Research and Development - The company's research and development expenses decreased by 24.13% to CNY 13.74 million[37]. - The company is cautious about R&D investments due to long cycles and market uncertainties, focusing on projects aligned with market demand[52]. Corporate Governance - The company held two shareholder meetings during the reporting period, with investor participation rates of 14.13% and 59.00% respectively[56]. - The company faced penalties related to information disclosure violations involving several directors and senior management, with warnings and fines issued by the China Securities Regulatory Commission[63]. - There were no major litigation or arbitration matters during the reporting period[62]. Market Outlook - The pharmaceutical industry is expected to continue stable growth due to increasing health awareness and an aging population in China[25]. - The company is focusing on expanding its marketing system and improving sales channels in response to the current medical reform policies[35]. Compliance and Reporting - The half-year financial report has not been audited[59]. - The company adheres to the accounting standards set by the China Securities Regulatory Commission, ensuring compliance in financial reporting[152]. - The financial statements are prepared based on the going concern principle, reflecting the company's financial position, operating results, and cash flows accurately[149][150]. Miscellaneous - The company has not engaged in any poverty alleviation initiatives during the reporting period and has no plans for future initiatives[81]. - There were no significant environmental issues reported, and the company complied with all relevant environmental protection laws[80]. - The company did not report any research and development expenses in both the first half of 2020 and 2019[122].

Financial Performance - The company's revenue for Q1 2020 was ¥157,012,600.06, representing a 131.69% increase compared to ¥67,767,425.29 in the same period last year[7] - Net profit attributable to shareholders was ¥10,309,269.64, a significant turnaround from a loss of ¥12,792,592.57 in Q1 2019, marking an increase of 180.59%[7] - The net profit after deducting non-recurring gains and losses was ¥11,271,079.81, compared to a loss of ¥12,906,020.79 in the previous year, reflecting a 187.33% improvement[7] - Basic and diluted earnings per share were both ¥0.0100, compared to a loss of ¥0.0124 per share in the same period last year, indicating an increase of 180.65%[7] - The weighted average return on equity was 1.67%, up from -2.16% in the previous year, showing a 3.83% improvement[7] - The company reported a significant increase in operating expenses, with management expenses rising by 56.39% to ¥27,676,474.80 from ¥17,697,559.46 due to business expansion costs[14] - The company recorded a 35149.13% increase in other operating expenses to ¥992,545.00 from ¥2,815.80, related to compensation payments to suppliers due to production suspension[14] - The operating profit for Q1 2020 was CNY 10.01 million, a significant recovery from a loss of CNY 13.98 million in Q1 2019[37] - The net profit for Q1 2020 was CNY 8.29 million, compared to a net loss of CNY 13.87 million in the previous year, indicating a turnaround in profitability[37] - The total comprehensive income for Q1 2020 was CNY 8.29 million, compared to a comprehensive loss of CNY 13.87 million in the same quarter last year[38] Cash Flow - The net cash flow from operating activities was ¥34,016,509.11, a 347.81% increase from a negative cash flow of ¥13,726,806.75 in Q1 2019[7] - Total cash inflow from operating activities was ¥123,976,196.16, while cash outflow was ¥89,959,687.05, resulting in a net cash inflow[45] - The company reported a net cash outflow from investing activities of ¥573,681.20, compared to a larger outflow of ¥1,287,510.00 in the previous year[45] - Cash flow from financing activities resulted in a net outflow of ¥54,299,308.25, a significant increase from the previous year's outflow of ¥1,278,750.01[46] - The total cash inflow from financing activities was ¥0.00, indicating no new borrowings or investments received during the quarter[46] - The company's cash flow from operating activities was CNY 123.92 million, an increase from CNY 88.87 million in the previous year, reflecting improved cash generation[44] Assets and Liabilities - Total assets at the end of the reporting period were ¥855,605,053.95, a decrease of 6.58% from ¥915,826,035.12 at the end of the previous year[7] - The total liabilities as of March 31, 2020, were CNY 119,464,910.61, showing a minor increase from CNY 119,389,765.98 at the end of 2019[33] - The company's total equity as of March 31, 2020, was CNY 595,759,445.61, a slight decrease from CNY 596,611,644.80 at the end of 2019[33] - Current liabilities reached CNY 253,774,281.05, with accounts payable at CNY 63,351,021.26[53] - Owner's equity totaled CNY 660,314,269.99, with total liabilities at CNY 255,511,765.13[54] Operating Performance - Operating revenue increased by 131.69% to ¥157,012,600.06 compared to ¥67,767,425.29, driven by increased sales in Guangxi Intercontinental[14] - Operating costs surged by 479.83% to ¥81,342,214.91 from ¥14,028,585.20, with material sales outpacing pharmaceutical sales but at a lower gross margin[14] - Total operating revenue for Q1 2020 was CNY 157,012,600.06, a significant increase from CNY 67,767,425.29 in the same period last year, representing a growth of approximately 131.5%[35] - Total operating costs for Q1 2020 amounted to CNY 144,823,734.07, compared to CNY 81,707,984.23 in Q1 2019, indicating an increase of about 77.2%[36] Research and Development - Research and development expenses decreased by 70.59% to ¥2,553,049.60 from ¥8,681,804.90 due to reduced outsourced R&D costs[14] - Research and development expenses decreased to CNY 2,553,049.60 in Q1 2020 from CNY 8,681,804.90 in the same period last year, reflecting a reduction of approximately 70.7%[36] - The company has a development expenditure of CNY 15,000,000.00, indicating ongoing investment in R&D[52] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 124,339[10] - Net assets attributable to shareholders increased by 1.68% to ¥623,837,698.34 from ¥613,528,428.70 at the end of the previous year[7] Miscellaneous - The company did not report any revenue from new product launches or technological advancements during this quarter[41] - There were no significant mergers or acquisitions reported in the first quarter of 2020[41] - The company has not provided specific guidance for future performance or market expansion strategies in this report[41] - The report indicates that the new revenue and leasing standards were not applicable for the first quarter[58] - The company has not undergone an audit for the first quarter report[59]

Financial Performance - The company's operating revenue for 2019 was CNY 417,878,239.86, representing a 5.65% increase compared to CNY 395,514,079.67 in 2018[18]. - The net profit attributable to shareholders in 2019 was CNY 14,330,773.52, a significant turnaround from a loss of CNY 29,439,589.94 in 2018, marking an increase of 148.68%[18]. - The net cash flow from operating activities reached CNY 58,632,435.61, up 159.82% from CNY 22,566,810.71 in the previous year[18]. - The basic earnings per share for 2019 was CNY 0.0139, compared to a loss of CNY 0.0286 per share in 2018, reflecting an improvement of 148.60%[18]. - Total assets at the end of 2019 were CNY 915,826,035.12, a slight decrease of 1.09% from CNY 925,876,050.58 at the end of 2018[18]. - The net assets attributable to shareholders increased by 2.39% to CNY 613,528,428.70 from CNY 599,197,655.18 in 2018[18]. - The weighted average return on equity improved to 2.36% in 2019 from -4.80% in 2018, indicating a positive trend in profitability[18]. - The company reported a significant increase in net profit after deducting non-recurring gains and losses, reaching CNY 9,968,680.96 in 2019, compared to a loss of CNY 30,237,281.18 in 2018, an increase of 132.97%[18]. Revenue Segmentation - The pharmaceutical segment generated ¥337,557,673.22, accounting for 80.78% of total revenue, but saw a decline of 3.71% year-on-year[38]. - The landscape engineering segment experienced a growth of 3.29%, with revenue of ¥28,162,408.25, up from ¥13,633,055.22 in the previous year[38]. - The ecological forestry segment reported revenue of ¥30,336,806.62, down 3.46% from the previous year[38]. - The company's domestic sales accounted for 97.64% of total revenue, amounting to 408,001,287.66 CNY, with a year-on-year increase of 4.69%[42]. - The total sales amount from the top five customers was 186,636,910.72 CNY, representing 44.65% of the annual sales total[51]. Research and Development - The company has established partnerships with several research institutions, enhancing its R&D capabilities with 5 invention patents and 3 new drug certificates[31]. - R&D expenses increased by 241.54% to ¥42,979,055.82, driven by outsourcing to enhance technology and efficiency[53]. - R&D investment reached ¥57,979,055.82, accounting for 13.87% of operating revenue, a significant increase from 3.18% in the previous year[57]. - The company aims to increase the annual production of recombinant human erythropoietin (EPO) by 20-30 times through large-scale cell culture technology, addressing a market demand gap of approximately 80g[55]. Operational Strategy - The company is actively expanding into new business areas, including medical devices and health management services[35]. - The company is focusing on technological innovation and internal management to adapt to the new normal of medical reform[34]. - The company has obtained construction qualifications, which are expected to increase its engineering business volume[35]. - The company has not made any changes to its main business since its listing, indicating stability in its operational focus[17]. Cost Management - Sales expenses decreased by 31.23% to ¥151,300,702.56 due to cost reduction efforts[53]. - The company is focusing on controlling production and procurement costs to improve overall cost management[73]. - Total operating costs decreased to CNY 387,011,303.39 from CNY 417,011,203.77, reflecting a reduction of approximately 7.2%[189]. Governance and Compliance - The company has established a governance structure to protect minority shareholders' rights and ensure compliance with relevant laws and regulations[106]. - The company has been subject to penalties for information disclosure violations, with warnings and fines issued by the China Securities Regulatory Commission[88]. - The company has not faced any major litigation or arbitration matters during the reporting period[87]. - The company has implemented new financial instrument standards starting January 1, 2019, following the Ministry of Finance's revised accounting standards[82]. Shareholder Information - The total number of shareholders at the end of the reporting period was 84,079, with the largest shareholder holding 14% of the shares[117]. - The largest shareholder, Wang Hongming, holds 144,138,394 shares, representing a significant portion of the company's equity[118]. - The company has not engaged in any repurchase transactions among its top 10 shareholders during the reporting period[118]. - The actual controller, Lu Keping, has been in control since at least May 23, 2014, as per regulatory documentation[121]. Employee Management - The total number of employees in the company is 331, with 324 in major subsidiaries and 7 in the parent company[142]. - The employee composition includes 144 production personnel, 23 sales personnel, 89 technical personnel, 17 financial personnel, and 58 administrative personnel[142]. - The total remuneration for the board and senior management during the reporting period is 167.92 million[141]. - Training programs are implemented to enhance the overall quality and business skills of employees, including both internal and external training[144]. Audit and Financial Reporting - The audit opinion issued by the accounting firm was a standard unqualified opinion, confirming the fair presentation of the financial statements[168]. - The company maintained effective internal controls over financial reporting, with no significant deficiencies identified[163]. - The audit report emphasizes the importance of internal controls related to inventory management and impairment provisions[171]. - The company is required to maintain necessary internal controls to prevent material misstatements in financial reporting[174].